Key clinical point: Afatinib appears safe and effective for elderly patients with non–small cell lung cancer.
Major finding: Elderly patients had 12-month progression-free survival rate of 62%.
Study details: A retrospective analysis of the GIDEON phase 3 trial.
Disclosures: Boehringer Ingelheim funded the study. The investigators did not report conflicts of interest.
Brückl et al. ELCC 2019. Abstract 125P.